Literature DB >> 9733501

Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships.

D M Benbrook1, S Subramanian, J B Gale, S Liu, C W Brown, M F Boehm, K D Berlin.   

Abstract

Heteroarotinoids are synthetic retinoids derived from trans-retinoic acid and the arotinoid structures and include a heteroatom in a five- or six-membered cyclic ring. This is the first systematic study of influences of the heteroatom, ring size, number of aryl groups, and terminal side chain on retinoid receptor specificity. Two new heteroarotinoids were synthesized and characterized. Although all heteroarotinoids activated RAR receptors, two dominant associations between structure and specificity were identified across all compounds. The six-membered ring conferred increased RARbeta specificity over the five-membered ring. The sulfur atom conferred greater specificity for RARgamma than the oxygen atom. RARalpha specificity was attenuated by a combination of influences from the heteroatom and aryl groups. In summary, the heteroatom and cyclic ring size exerted dominant effects, while the number of aryl rings and terminal side chain had attenuating effects on retinoid receptor specificity of heteroarotinoids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733501     DOI: 10.1021/jm980308p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.

Authors:  Doris M Benbrook; Scott A Kamelle; Suresh B Guruswamy; Stan A Lightfoot; Teresa L Rutledge; Natalie S Gould; Bethany N Hannafon; S Terence Dunn; K Darrell Berlin
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

2.  Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.

Authors:  Tashanna Myers; Shylet Chengedza; Stan Lightfoot; Yanfang Pan; Daynelle Dedmond; Lauren Cole; Yuhong Tang; Doris M Benbrook
Journal:  Invest New Drugs       Date:  2008-09-18       Impact factor: 3.850

3.  Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis.

Authors:  Felix A Mic; Andrei Molotkov; Doris M Benbrook; Gregg Duester
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

Review 4.  Retinoids: novel immunomodulators and tumour-suppressive agents?

Authors:  M R Carratù; C Marasco; G Mangialardi; A Vacca
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

5.  Novel retinoic acid receptor alpha agonists for treatment of kidney disease.

Authors:  Yifei Zhong; Yingwei Wu; Ruijie Liu; Zhengzhe Li; Yibang Chen; Todd Evans; Peter Chuang; Bhaskar Das; John Cijiang He
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

Review 6.  SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention.

Authors:  Doris Mangiaracina Benbrook
Journal:  Front Cell Dev Biol       Date:  2022-02-23

7.  Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

Authors:  Doris M Benbrook; Stan Lightfoot; James Ranger-Moore; Tongzu Liu; Shylet Chengedza; William L Berry; Igor Dozmorov
Journal:  Gene Regul Syst Bio       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.